Palbociclib - from Bench to Bedside and Beyond.
TL;DR: In conclusion, inhibition of CDK4/6 using palbociclib in combination with endocrine therapy is an efficacious treatment option in hormone receptor-positive/HER2-negative advanced breast cancer.
read more
Abstract: Endocrine therapy is the cornerstone in the treatment of hormone receptor-positive breast cancer. During the last decades, much has been learned about the subtle regulation of the cell cycle. In this tightly regulated network, cyclin-dependent kinases (CDKs) play a pivotal role. Especially CDK4/6 is the key regulator of the G1-S transition. Realizing its importance, specific inhibitors of CDK4/6 were developed. The drug most advanced in clinical development in this class is palbociclib (PD 0332991). This review highlights preclinical data and brings into focus early clinical trials that led to an accelerated approval by the US Food and Drug Administration (FDA) as first-line treatment in combination with letrozole in advanced hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Furthermore, ongoing clinical trials with palbociclib in advanced and in early breast cancer are outlined. In conclusion, inhibition of CDK4/6 using palbociclib in combination with endocrine therapy is an efficacious treatment option in hormone receptor-positive/HER2-negative advanced breast cancer. Ongoing clinical trials will show whether palbociclib is ready for prime time in early breast cancer.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
Reece G. Kenny,Celine J. Marmion +1 more
TL;DR: This review has endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities associated with modern day chemotherapeutics but also address resistance issues that are plaguing many Chemotherapeutic regimens.
535
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions.
Rossana Roncato,Jacopo Angelini,Arianna Pani,Erika Cecchin,Andrea Sartore-Bianchi,Salvatore Siena,Elena De Mattia,Francesco Scaglione,Giuseppe Toffoli +8 more
TL;DR: A personalized therapeutic approach taking into consideration all factors potentially contributing to an altered pharmacokinetic/pharmacodynamic profile could better drive safe and effective clinical use of CDKis.
58
Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9
Grégoire Cullot,Julian Boutin,Florence Prat,J. F. Rosier,David Cappellen,Isabelle Lamrissi,Perrine Pennamen,Julie Bouron,Samuel Amintas,Isabelle Moranvillier,Elodie Laharanne,Jean-Philippe Merlio,Véronique Guyonnet-Dupérat,Jean-Marc Blouin,Edo Richard,Sandrine Dabernat,François Moreau-Gaudry,Aurélie Bedel +17 more
TL;DR: These tools reveal rare complex chromosomal rearrangements caused by Cas9-nuclease and show that LOH frequency depends on cell division rate during editing and p53 status, and cell cycle arrest during editing suppresses the occurrence of LOH without compromising editing.
16
Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer
Anand A. Dalal,Patrick Gagnon-Sanschagrin,Rebecca Burne,Annie Guerin,Geneviève Gauthier,Tania Small,Polly A. Niravath +6 more
TL;DR: This study showed that drug wastage due to palbociclib dose modification results in substantial costs, and treatment options with more flexible dosing may help reduce the costs of drug wastages.
12
Anti-cancer drug molecules targeting cancer cell cycle and proliferation.
TL;DR: The role of cell cycle regulators and proliferation factors in cancer progression and the rationale of using various cell cycle-targeting drug molecules as anti-cancer therapy was analyzed in this paper . But, the authors did not consider the effect of cell proliferation factors on the cell cycle.
9
References
Hallmarks of cancer: the next generation.
TL;DR: Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.
63.3K
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn,John Crown,István Láng,Katalin Boér,Igor Bondarenko,Sergey O. Kulyk,Johannes Ettl,Ravindranath Patel,Tamás Pintér,Marcus Schmidt,Yaroslav Shparyk,Anu Thummala,Nataliya L. Voytko,Camilla Fowst,Xin Huang,Sindy T. Kim,Sophia Randolph,Dennis J. Slamon +17 more
TL;DR: Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen receptor-positive breast cancer cells and synergy with anti-oestrogens as mentioned in this paper.
1.8K
To cycle or not to cycle: a critical decision in cancer.
TL;DR: Tumour cells undergo uncontrolled proliferation, yet tumours most often originate from adult tissues, in which most cells are quiescent, so the proliferative advantage of tumour cells arises from their ability to bypass quiescence.
1.6K
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn,Judy Dering,Dylan Conklin,Ondrej Kalous,David Cohen,Amrita J. Desai,Charles Ginther,Mohammad Atefi,Isan Chen,Camilla Fowst,Gerret Los,Dennis J. Slamon +11 more
TL;DR: A role for CDK4/6 inhibition in some breast cancers is suggested and criteria for patient selection in clinical studies of PD 0332991 is identified.
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Nicholas C. Turner,Jungsil Ro,Fabrice Andre,Sherene Loi,Sunil Verma,Hiroji Iwata,Nadia Harbeck,Sibylle Loibl,Cynthia Huang Bartlett,Ke Zhang,Carla Giorgetti,Sophia Randolph,Maria Koehler,Massimo Cristofanilli,Massimo Cristofanilli +14 more
TL;DR: Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrants alone.